| ||
| A benefit-risk assessment of erlotinib in non-small-cell lung ... Non-small-cell lung cancer (NSCLC) and pancreatic cancer represent two major ... been approved for the first- or second-line treatment of locally advanced, ... www.docguide.com/benefit-risk-assessment-erlotinib-non-sma... |
Tip: Use a minus sign (-) in front of terms in your query that you want to exclude. Learn more.
Remove this alert.
Create another alert.
Manage your alerts.
No comments:
Post a Comment